Nubeqa (Darolutamide), a Hormone Therapy | Ask a Prostate Expert, Mark Scholz, MD

Nubeqa (darolutamide) was FDA approved to treat the M0 stage of prostate cancer in late 2019. Now that it is available nationwide, Alex and Dr. Scholz discuss its role in the prostate cancer world as of 2021. 0:05 What is Nubeqa and how has it changed the prostate cancer world? 1:47 How do the side effects of Nubeqa compare to other second-generation anti-androgens (Zytiga, Xtandi, Erleada)? 2:11 Nubeqa was approved to treat the M0 state of prostate cancer, but could it be used in other stages? 2:57 Is there a benefit to taking Nubeqa earlier in the disease timeline? Don’t know your stage? Take the quiz: Visit http://www.prostatecancerstaging.org To learn more about prostate cancer visit http://www.pcri.org Who we are: The Prostate Cancer Research Institute (PCRI) is a 501(c)(3) not-for-profit organization that is dedicated to helping you research your treatment options. We understand that you have many questions, and we can help you find the answers that are specific to your case. All of our resources are designed by a multidisciplinary team of advocates and expert physicians, for patients. We believe that by educating yourself about the disease, you will have more productive interactions with your medical professionals and receive better-individualized care. Feel free to explore our website or call our free helpline at 1 (800) 641-7274 with any questions that you have. Our Federal Tax ID # is 95-4617875 and qualifies for maximum charitable gift deductions by individual donors. The information on the Prostate Cancer Research Institute's YouTube channel is provided with the understanding that the Institute is not engaged in rendering medical advice or recommendation. The information provided in these videos should not replace consultations with qualified health care professionals to meet your individual medical needs. #ProstateCancer #Prostate #MarkScholzMD